Theo de Boer, PhD, principal scientist - scientific director LCMS, Ardena shares the key steps to bring ADCs successfully to clinical trial.
The use of antibody-drug-conjugates (ADC) in drug development is becoming more and more widespread, thanks to their potential to improve the effectiveness of cancer treatments by enabling more precise targeting of cancerogenic cells. ADCs harness a mechanism based on an antigen-mediated uptake of a cytotoxic drug, which is then released directly into target cancer cells - by achieving this while avoiding healthy cells, they enhance efficacy with reduced adverse side effects.